

Oncology Today with Dr Neil Love: Hodgkin Lymphoma Edition  
(Video Presentation)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. On the Phase III ECHOLON-1 trial, which of the following regimens resulted in a progression-free survival advantage compared to standard doxorubicin/bleomycin/vinblastine/dacarbazine (ABVD) as first-line therapy for patients with Stage III or IV classical Hodgkin lymphoma (cHL)?
  - a. Bendamustine + doxorubicin/bleomycin/vinblastine/dacarbazine (ABVD)
  - b. Nivolumab + ABVD
  - c. Brentuximab vedotin (BV) + doxorubicin/vinblastine/dacarbazine (AVD)
  - d. BV + nivolumab
2. The ongoing US Intergroup Phase III study SWOG-S1826 is evaluating which of the following regimens for patients with newly diagnosed advanced-stage cHL?
  - a. AVD + BV versus AVD + pembrolizumab
  - b. ABVD versus AVD + nivolumab
  - c. ABVD versus AVD + BV
  - d. AVD + BV versus AVD + nivolumab
3. Which of the following anti-PD-1/PD-L1 antibodies resulted in a progression-free survival advantage when compared to BV for patients with relapsed/refractory cHL on the Phase III KEYNOTE-204 trial?
  - a. Avelumab
  - b. Nivolumab
  - c. Pembrolizumab
4. What was the median number of cycles of consolidation BV administered on the Phase III AETHERA trial, which evaluated BV as consolidation therapy after autologous stem cell transplant for patients with cHL at high risk of relapse or disease progression?
  - a. 8
  - b. 11
  - c. 16